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Immunology researchers are beginning to explore the possibilities of reproducibility, reuse and
secondary analyses of immunology data. Open-access datasets are being applied in the validation of
the methods used in the original studies, leveraging studies for meta-analysis, or generating new
hypotheses. To promote these goals, the ImmPort data repository was created for the broader
research community to explore the wide spectrum of clinical and basic research data and associated
findings. The ImmPort ecosystem consists of four components–Private Data, Shared Data, Data
Analysis, and Resources—for data archiving, dissemination, analyses, and reuse. To date, more than
300 studies have been made freely available through the Shared Data portal (immport.org/immport-
open), which allows research data to be repurposed to accelerate the translation of new insights into
discoveries.
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Introduction
Recent advances in high-throughput technologies, coupled with a massive accumulation of multi-scale
data, has created an exciting opportunity for secondary data usage in many different areas1,2. ImmPort is
one of the largest open repositories of subject-level human immunology data, with a commitment to
promoting effective data sharing across the basic, clinical and translational research communities3.
ImmPort collects data both from clinical and mechanistic studies on human subjects and from
immunology studies on model organisms. Currently, de-identified datasets from more than 300 studies
are shared through the repository with a primary focus on allergy, autoimmune diseases, infection
responses, transplantation, and vaccine responses. Data and accompanying software tools are made
available to the public through the ImmPort portal (http://www.immport.org/).
ImmPort is also in the vanguard of efforts to formulate and implement the standards and guidelines
and demonstrate the potential of immunological assay data meta-analysis. In general, complex datasets
pose challenges to data discoverability, reproducibility, and reuse. Metadata documenting data
provenance can play a crucial role in overcoming these challenges4. The ImmPort database architecture
is designed to support and maintain a variety of multi-modal immunological data such as study method
documentation, metadata and standardized data formats and terminologies. Together, these efforts
facilitate accurate and efficient secondary analysis of large-scale immunology data.
ImmPort was created as part of the National Institute of Allergy and Infectious Diseases Division of
Allergy, Immunology and Transplantation (NIAID-DAIT) implementation of the NIH Data Sharing
policy (https://grants.nih.gov/policy/sharing.htm) to promote the principles of Findability, Accessibility,
Interoperability and Reusability (FAIR; https://www.force11.org/group/fairgroup/fairprinciples). In
addition to collecting, curating, and sharing data from NIAID-funded clinical research projects,
ImmPort now extends to embrace data from other NIH programs, including the National Institute of
Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Cancer Institute (NCI), and also
from privately funded researchers and collaborations.
Results
The goal of ImmPort is to ensure that basic and clinical research data are accessible to researchers in ways
that allow effective sharing of data and knowledge. In order to facilitate this process, the ImmPort
ecosystem includes four major applications: Private Data, Shared Data, Data Analysis, and Resources.
Immunology research data are collected and curated in the Private Data application with access
controlled by data providers and later published through the Shared Data application for open access.
ImmPort Galaxy (immportgalaxy.org) is a Data Analysis application based on the Galaxy framework5
to encourage use of open source cytometry analysis tools by making command line tools available in a
graphical user interface. The Resources application provides tutorials, customized reference datasets, and
data mining and analytical tools to explore the ImmPort data model and analyze its content.
In typical consortium settings, data management practices are focused on making data available to
domain experts located at multiple sites for analysis and interpretation. However, collocation of
multimodal data across a consortium often leads to redundancies that complicate the iterative quality
control processes inherent in research data analysis. With ImmPort, all the data collected from any given
clinical trial project or investigative consortium reside in a single repository. This allows research teams to
demonstrate the breadth of their activities from data reporting to deposition in ways that go beyond the
limitations of a publication. It also enables external investigators to discover the content, merge across
data sets, and generate and test new hypotheses and insights. Moreover, ImmPort provides a one-step
registration process that ensures compliance with the key elements of the NIAID-DAIT Data Sharing Use
Agreement (http://www.immport.org/agreement). As of the January 2018 data release, ImmPort shares
309 studies, 1369 experiments, 236 lab test panels, and 449 assessments (clinical, experimental or
questionnaire based) from 50,180 human and animal subjects.
Data Collection
The ImmPort data collection, curation, and sharing process is the product of extensive prototyping and
refinement involving DAIT Program Officers, data providers, the ImmPort data curation team, and the
researchers who use the shared data. Fig. 1 shows a schematic representation of this process. For an
initiative of this scale to work, it is essential that the data is provided with sufficient descriptions and
content in well-defined formats that will enable effective discovery and analysis. This requirement is not
always aligned with the practices and priorities of the researchers who provide the data. ImmPort
customizes its engagement with data providers to meet their needs and capabilities while at the same time
maximizing the quality of the data content and annotations which are provided.
To this end, the ImmPort has developed a set of data upload templates (http://www.immport.org/
immport-open/public/home/dataTemplates) through which key elements of biomedical research data are
annotated with a consistent set of descriptors. The templates are informed by community standards, and
ImmPort coordinates with domain experts and standards governing bodies to upgrade and extend them
to meet the needs of data providers. These templates and associated rules form the initial component of
ImmPort data quality control. The data model is an aggregation of clinical and mechanistic data models
from sources including Clinical Data Interchange Standards Consortium (CDISC; www.cdisc.org/),
Generic Model Organism Database project (GMOD; http://gmod.org/) and Gene Expression Omnibus
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(GEO; https://www.ncbi.nlm.nih.gov/geo) to support immunological studies. The descriptions of studies,
subjects, samples, measurements and study related metadata are captured in a relational data model
(Fig. 2).
ImmPort encounters a large number of nomenclature variants across a wide spectrum of assay and
assessment methods from the data providers when describing their experiments. In order to facilitate data
harmonization, ImmPort has introduced standard vocabularies in the data templates to encourage data
providers to use standard terms. The ImmPort data upload and curation process aims to improve the
consistency with which, for example, the names of viral strains, cell surface markers, cell population
definitions, lab test panels, biomarkers, assays, and assessments are displayed (see Methods).
Human Study Participant Safeguards
ImmPort adheres to best practices in properly de-identifying human study participants. Thus, the data
elements restricted by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)6 are not
captured by ImmPort (See Methods). The subject metadata includes standard demographic attributes
such as age, gender, race, ethnicity and additional details, and for assay data modalities (e.g., genotyping
and sequencing based assays) deemed by NIH to be potentially sensitive to re-identification, ImmPort
recommends data providers upload their data to an appropriate data repository such as the Database of
Genotypes and Phenotypes (dbGAP)7 and the Sequence Read Archive (SRA).8
Clinical Trials
Clinical data sharing practices have come under increasing scrutiny with calls for improvements
including the reporting of negative or contradictory results and to allow independent verification of
findings on the basis of individual patient-level data (http://www.nationalacademies.org/hmd/activities/
research/sharingclinicaltrialdata.aspx)9,10. ImmPort is the designated data sharing portal for NIAID-
DAIT funded clinical trials, which include investigations into allergy, asthma, autoimmunity, infection,
transplantation, and vaccine response. The ImmPort team works closely with data providers to ensure all
data sets listed in case report forms, data dictionaries, publications, and study protocols are uploaded and
accurately annotated. The associated clinical trials are cross-referenced with ClinicalTrials.gov and
complement the latter by providing subject level results. Data from 65 clinical trials have thus far been
shared through ImmPort.
Figure 1. ImmPort Data Flow. The ImmPort ecosystem is composed of four applications: Private Data,
Shared Data, and Data Analysis and Resources. Private Data is the data acquisition and curation site, Shared
Data supports searching and distribution of data, Data Analysis provides a graphic interface for open source
data management and analysis tools primarily focused on flow cytometry results, and Resources provides
advanced data analysis tools, tutorials, documentation. This schematic representation shows the steps of data
capture, data curation, and secondary usage of ImmPort studies by different entities. The solid line denotes an
example flow of cytometry data across the four applications.
www.nature.com/sdata/
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Finding and Distribution of Shared Data
In recent years, ImmPort has introduced new features to facilitate fast and flexible querying across
hundreds of datasets and research domains in a time-efficient manner. The Shared Data application
incorporates a Data Catalog feature which supports searching of research data based on studies,
biomarkers, experiments, assessments, and lab tests (Insert data catalog link). Subject level data is
available in tab separated value (TSV) and MySQL formats. Users can choose between downloading
study-specific or all shared data content. Application Programming Interfaces (APIs) are available which
allow user specified extraction of data subsets based on research interest (docs.immport.org).
Furthermore, ImmPort promotes educational outreach by developing tutorials which include how to
use the ImmPort APIs, descriptions of the ImmPort Data Model, basics of programming and data
analysis, as well as tutorials for the use of ImmPort Galaxy and data uploading to ImmPort for
subsequent sharing. Concurrently, descriptive tutorials for secondary usage of data are made available
for basic bench scientists in Jupyter (jupyter.org) notebooks using the R (www.R-project.org) and Python
(www.python.org) programming languages (Fig. 3).
ImmPort Galaxy for Data Analysis
ImmPort Galaxy is the Data Analysis application and seeks to promote the use of open source analysis
tools applied to both conventional flow cytometry and mass cytometry (CyTOF, Cytometry Time of
Flight) by providing a graphical interface for their use. This removes the barrier the standard command
line interfaces pose for many immunologists11. ImmPort Galaxy adopts the framework established by the
Galaxy Project established in making code freely available to the wider scientific community. The
adaptation of the Galaxy framework to host flow analysis tools such as FLOCK12 and FlowSOM13 also
Figure 2. ImmPort Data Model. This figure illustrates the relationship between the nodes linking to a detailed
description of the term in the ImmPort data model. The color of nodes represents the types of information
stored in the ImmPort database tables.
www.nature.com/sdata/
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addresses several data analysis challenges identified by ImmPort users in providing easier file upload,
support for high-throughput analysis, and flexibility to integrate new tools (Fig. 4).
ImmPort as a Community Resource for Data Reuse
ImmPort works with a number of consortiums to facilitate data curation and sharing between
participating laboratories. The major multi-center projects includes the NIH Accelerating Medicines
Partnership (AMP; https://niams.nih.gov/grants-funding/funded-research/accelerating-medicines) for
Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) seeking to define shared and
disease-specific biological pathways to identify relevant drug targets for the treatment of autoimmune
diseases, and the NIAID Human Immunology Project Consortium (HIPC; www.immuneprofiling.org)
which characterizes human immune responses/mechanisms elicited by vaccinations, adjuvants or natural
infection by capitalizing on recent advances in immune profiling technologies. ImmPort also provides
curated data sets to ImmuneSpace (https://www.immunespace.org), the HIPC data analysis resource. In
addition, ImmPort supports data collection for the National Cancer Institute (NCI) Oncology Model
Forum (OMF; http://oncologymodels.org) and its projects to assess the quality and fidelity to human
cancer of syngeneic (genetically identical) Genetically Engineered Mouse Models (GEMMs) and Patient
Derived Xenografts (PDXs). In addition to government funded initiatives, ImmPort provides the March
of Dimes (https://www.marchofdimes.org) Prematurity Research Centers with services to disseminate
shared data resources (http://www.immport.org/resources/mod).
In the field of Immunology, the possibilities of reuse and repurposing of shared datasets are only now
beginning to be explored both for validation of the methods used in their origination, but also for the
creation of new knowledge through meta-analysis or through virtual testing of hypotheses not foreseen by
the original authors. For example, our team reused the ANCA-Associated Vasculitis (RAVE) trial dataset
in ImmPort (SDY91) to distinguish between patients who achieved remission at 6 months following
Rituximab or cyclophosphamide treatment, and ‘control’ patients for whom their Rituximab treatment
failed. We were able to identify distinct subsets of granulocytes as novel early markers in a subset of the
patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This re-analysis
led to novel insights and to a discovery which may better inform future clinical trials and therapies in
AAV14.
Here, we describe three projects we are pursuing for secondary analyses. The first aims to repurpose
ImmPort data to address the lack of a benchmark reference human ‘immunome’ comparable to what we
have in the realm of model organism genomes. We achieve this by using all of the data relating to healthy
Figure 3. ImmPort Tutorials. The ImmPort team maintains a library of tutorials under the Resources
application to highlight the programing tools used to explore, retrieve and analyze shared data (http://immport.
org/resources/tutorials).
www.nature.com/sdata/
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controls obtained from the myriad of shared clinical trials and research studies within ImmPort. The
result is the ‘10,000 Immunomes’ Resource15, a human reference data set comprising over thirteen types
of measurements standardized and harmonized across the population of roughly 10,000 healthy controls,
which is freely available for downloads and interactive visualizations (10kimmunomes.ucsf.edu/).
The second project takes advantage of the plethora of ImmPort shared flow and mass cytometry data
across several human populations and combines them in a systematic manner. To make this possible, we
developed a platform-agnostic, user-friendly, flow analysis framework called MetaCyto16 that allows
cytometry data combined from multiple sources to identify demographic specific differences in
circulating immune cell populations. MetaCyto is available as a R package on Bioconductor (www.
bioconductor.org/packages/release/bioc/html/MetaCyto.html) and on the Immport Galaxy platform.
Our third project repurposes ImmPort data relating to living donors in solid organ transplantation.
The curated ImmPort dataset has post-donation outcomes for kidney living donors, with a substantial
subset having post-donation long-term outcome. This presents an opportunity to map the possible
trajectories and sequence of events of living donors after they donate. Using such a ‘trajectory map’, we
can investigate patterns of kidney donor survival and outcomes, trajectories, and the survival of kidney
donors. We also foresee such an approach can be used in examining other temporal events, such as
adverse drug events in clinical trial subjects. This type of data visualization tool will be made available
through the Resources application.
Figure 4. ImmPortGalaxy. The ImmPort Data Analysis application offers a platform to run command line
analysis tools with a graphical user interface. ImmPort Galaxy supports creation and editing of workflows, tools
chained together in a user-defined fashion (a) Available tools allow users to go from Flow Cytometry Data basic
exploration (b) to multi-sample analysis (c, d).
www.nature.com/sdata/
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In addition, we are also developing data mining and access tools to facilitate data-driven knowledge in
Immunology. To date, many principles of individual cell behavior and inter-cellular circuitry have been
identified. To address the resultant deluge of knowledge and to establish a foundation for systematic
reasoning over the immune system inter-cellular network we built immuneXpresso, the first
comprehensive high-resolution searchable repository of interactions between cell types and regulatory
molecules identified from natural language processing of PubMed abstracts. immuneXpresso identifies
directional relations between more than 300 cell types and 140 signaling molecules across thousands of
diseases. This global high-resolution interaction map enables systematic prediction of novel cell-type-
specific interactions17. The tool is freely accessible from the ImmPort Resources application (www.
immport-labs.org/immport-immunexpresso/public/immunexpresso/search).
The descriptive and interpreted results data in ImmPort are structured in a relational data model.
Noting that the complexity of the data model makes accessing specific data for analysis or integrating
data across studies a potential challenge for researchers, we developed RImmPort18 to aggregate and
format ImmPort data for analysis in the R statistical environment. To aid in the secondary use of
ImmPort data, RImmPort implements a data model based on the CDISC clinical trial data standards, and
supports a suite of functions that facilitate the data retrieval.
Furthermore, there are insightful discoveries made by other researchers from the secondary analyses of
published studies from ImmPort. Khatri et al. identified a set of gene expression signatures from the
blood that might help to predict the antibody responses to influenza vaccination in young individuals
prior to vaccination19. Another data reuse example was demonstrated by a group that has retrospectively
analyzed a time-series RNA-seq dataset from human peripheral blood cells20 to infer the distinct
antibody repertoire response in individuals vaccinated with influenza vaccine21. Recently, a knowledge
base resource was published by leveraging the gene expression and cytometry based cell phenotyping data
from publicly accessible data sets (including ImmPort) as a validation set for in silico analyses22. This
demonstrates the flexibility and richness of ImmPort database as a valuable data resource in
Immunology.
Discussion
ImmPort is a curation and distribution portal for promoting re-use of immunological research data
generated by NIAID and other NIH programs and privately funded investigators. ImmPort provides
comprehensive subject-level information from shared studies, including study design, adverse events,
assessments, interventions, lab tests, medical histories, experiments and details on methods of data
generation. Here we describe ImmPort’s core capabilities in making shared data Findable, Accessible,
Interoperable, and Reproducible. We additionally highlight examples of reusing the clinical and
mechanistic data to gain novel insights and building reference datasets and tools to benefit the
community. ImmPort seeks to grow the community of shared data and open science practitioners by
providing tools to search and analyze data reproducibly and tutorials to explain the data and illustrate its
possibilities. The deployment of an Application Programming Interface (API) will facilitate the data
exchange and interoperability within and across other resources. There is a continuing effort to engage a
growing community of users which includes experimental immunologists, data-driven modelers and data
enthusiasts to take advantage of the enriched ImmPort datasets deposited by large consortia and
individual labs in the Immunology community.
Method
Sources for Standard Terms
ImmPort data is annotated with terms from several ontologies including Cell Ontology23, Disease
Ontology (disease-ontology.org), Ontology for Biomedical Investigations (OBI; obi-ontology.org),
Protein Ontology24, and Vaccine Ontology25. MedDRA (www.meddra.org) is used for adverse event
terms and the NCI Thesaurus supplies terms from a variety of sources (e.g., CDISC). The Antibody
Ontology (AntiO) is a new resource developed from data curated in ImmPort to provide standardized
representation of monoclonal antibodies used in immunology research26. Along with updates to OBI, it
exemplifies the ongoing development of data standardization facilitated by ImmPort. An analogous
problem arises in the case of cytokines, where no public domain registry has thus far been available. To
fill this gap, a registry of cytokines, chemokines and their receptors was compiled (http://www.immport.
org/immport-open/public/reference/cytokineRegistry) for the purpose of collecting, integrating, and
mapping between entity names and synonyms. The cytokine registry draws on resources such NCBI
Gene, HGNC, MGI, Protein Ontology, and UniProt. ImmPort engages with several data standards
communities such as the Human Immune Phenotyping Consortium (HIPC) Standards Working
Group18, BioSharing (fairsharing.org), the Patient Derived Tumor Xenograft Minimal Information
(PDX-MI) working group27 and the NIH Big Data to Knowledge (BD2K) initiative (datascience.nih.gov/
bd2k/about) through its collaboration with CEDAR (http://metadatacenter.org).
ImmPort Tools and Resources
MetaCyto. MetaCyto is a computational pipeline that performs automated meta-analysis of cytometry
data. It allows the joint analysis of heterogeneous cytometry studies, such as studies with batch effects or
www.nature.com/sdata/
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studies using non-identical antibody panels. MetaCyto is available on GitHub (github.com/hzc363/
MetaCyto) and on Bioconductor (http://bioconductor.org/packages/release/bioc/html/MetaCyto.html).
RImmPort. RImmPort is an R-driven interface to ImmPort data based on the CDISC clinical trial data
standards. RImmPort supports standard data queries and analyses, and facilitates data integration across
studies in ImmPort and potentially, in other repositories. The RImmPort package is released in R/
Bioconductor (bioconductor.org/packages/RImmPort).
AntiO. AntiO provides metadata that links antibody products not only to the vendors and vendor
catalog information but also to the clone that produced the antibody, their protein targets, and their
fluorescent conjugations. This information is provided in an ontology form that allows for advanced
querying for antibodies and their targets, so that one can easily identify, for instance, all PE-labeled anti-
CD25 antibodies, their vendors and catalog numbers, and the ImmPort studies in which they were
employed.
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